Clinical Trials

Inclusion Criteria: -MRI findings compatible with newly diagnosed or recurrent high- or low-grade malignant glioma -Planned craniotomy and resection or biopsy -Willing to sign release of information for any radiation and/or follow-up records -Provide informed written consent if >= 18 years; if < 18 years, provide informed written assent and parent or legal guardian provide informed written consent -Ability to provide tissue for mandatory correlative research component Exclusion Criteria: -Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator, kidney failure) -Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's disease, taking anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from discontinuance of dopamine agonists; NOTE: other potentially interfering drugs: amoxapine, amphetamine, benztropine, buproprion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, paroxetine, citalopram, and sertraline; if a patient is on any of these drugs, list which ones on the on-study form -Any of the following: -Pregnant women -Nursing women -Men or women of childbearing potential who are unwilling to employ adequate contraception